Clinical trials: HPV
HNSCC
Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)
This is a Phase II single-arm window trial to assess the clinical and biological effects of neoadjuvant abemaciclib in patients with HPV-negative head and neck squamous cell carcinoma (HNSCC).
- Trial name
- NCT04169074
- Testing
- Abemaciclib
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Arizona
Human Papillomavirus Vaccination
Can an Educational Intervention Targeting General Practitioners Increase HPV Vaccination Coverage in AuRA_Lyon (France)
The PAPRICA implementation trial aims to test the efficacy of an educational intervention about HPV vaccination and targeting general practitioners in Lyon
- Trial name
- PAPRICA (NCT03592225)
- Testing
- Educational workshop
- Where
- France
- Volunteers
- 300 people
- Sponsor
- International Agency for Research on Cancer
Cervical Cancer
Safety and Immunogenicity Study of Human Papilloma Virus Vaccine in Women Aged 9 to 30 and Men Aged 9 to 17
This study evaluates the safety of Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha) in women of 9 to 30 years old and men of 9 to 17 years old and preliminarily explore the…
- Trial name
- NCT02888418
- Testing
- Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha)
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Beijing Chaoyang District Centre for Disease Control and Prevention
Human Papillomavirus Infection
HPV Vaccination in Women With Cystic Fibrosis
The main risk factor for the development of cervical lesions is human papillomavirus (HPV) infection. Vaccination against human papillomavirus, which is offered to all girls aged 11 to 14, and catching up to girls aged 15 to 19…
- Trial name
- VACCIN-HPV-MUC (NCT03265743)
- Testing
- Self-report Written Questionnaire
- Where
- 3 sites in France
- Volunteers
- 74 people
- Sponsor
- Hospices Civils de Lyon
Verruca Vulgaris
Photodynamic Therapy in Treatment of Verrucae
To assess the efficacy (clinically and dermoscopically) and safety of photodynamic therapy using intralesional injection of 4% methylene blue solution as a photosensitizer with IPL versus IPL only in treatment of warts.
- Trial name
- NCT04620785
- Testing
- methylene blue / IPL, IPL, saline
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Alexandria University
HIV Infections, Papilloma
The Effects of Combination Anti-HIV Medication on Human Papillomavirus (HPV) in HIV-Infected Women
The purpose of this study is to see how often human papillomavirus (HPV) occurs in HIV-infected women who have not taken anti-HIV drugs and to learn whether taking anti-HIV drugs will affect HPV in women.
- Trial name
- NCT00006444
- Where
- 51 sites in United States, Puerto Rico
- Volunteers
- 160 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B, Human Papilloma Virus
Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.
Aim: The main goal of this quantitative epidemiological observational study is to determine the prevalence of Human Papilloma Virus (HPV) infection and Hepatitis B (Hep B) immunity amongst women of childbearing age.
- Conditions
- Hepatitis B, Human Papilloma Virus, Mental Health Issue, Cancer Liver
- Trial name
- NCT06786429
- Testing
- Gardasil 9 vaccine, Hepatitis B Virus Vaccine(HBV), Cognitive Behavioral Therapy
- Volunteers
- 2,140 people, healthy volunteers welcome
- Sponsor
- Eunice Dube
Human Papilloma Virus (HPV) Vaccine
Knowledge, Attitude &Practice on Human Papilloma Virus Vaccination Among Healthcare Providers and General Population
Cervical cancer is caused by persistent infection with certain strains of the human papillomavirus (HPV), which is a very common virus transmitted through sexual activity.
- Trial name
- NCT06743880
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Assiut University
Human Papilloma Virus Infection
Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine
The aim of the study is to develop and implement robust analytical protocols for first-void urine sample preparation and antibody assays to monitor vaccine induced immunity against HPV (Human Papillomavirus).
- Trial name
- ABSOP-FollowUp (NCT03542227)
- Testing
- First-void urine collection, Blood draw
- Where
- Belgium
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Universiteit Antwerpen
Cancer Survivor, Prevention of Human Papillomavirus Infection
Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors
This trial will comprehensively evaluate the human papillomavirus (HPV) vaccine in cancer survivors between 9 and 26 years of age by (1) determining the prevalence of HPV vaccine initiation among young cancer survivors, and (2)…
- Trial name
- NCT01492582
- Testing
- quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58), laboratory biomarker analysis, survey administration
- Where
- 5 sites in United States
- Volunteers
- 1,499 people
- Sponsor
- University of Alabama at Birmingham
HPV Vaccine
Persistence of Immune Response Six Years After One Dose of 9vHPV Vaccine Among Male and Female Students
Since the 2019-2020 school year, the province of Quebec (Canada) has been administering one dose of nonavalent (9vHPV) vaccine to students of all genders in Grade 4 of elementary school through the school-based program.
- Trial name
- CIRN-HPV-ONE (NCT07156084)
- Testing
- HPV nonavalent vaccine (Gardasil-9)
- Where
- Canada
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Canadian Immunization Research Network
Papillomavirus Infections
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)
The purpose of this study is to evaluate the safety and tolerability of the Quadrivalent Human Papilloma Virus (HPV) vaccine in healthy females 9 to 15 years of age in India.
- Trial name
- NCT00380367
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer, Vulvar Cancer
A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)
The purpose of this study is to evaluate vaccine immunogenicity and how well the body tolerates V504 when given with Gardasil.
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT00551187
- Testing
- V504, Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Intraepithelial Neoplasia, Cervix Uteri Cancer
Incidence of Cervical Cancer in HPV-positive Women With Low-grade Cytological Abnormalities
The goal of this observational study is to assess the five-year incidence of histologically confirmed cervical cancer among women who test positive for human papillomavirus (HPV) with low-grade cytological abnormalities, to…
- Conditions
- Cervical Intraepithelial Neoplasia, Cervix Uteri Cancer, Human Papilloma Virus, Cervix Carcinoma
- Trial name
- NCT07259616
- Volunteers
- 46,079 people
- Sponsor
- Gynaecologisch Oncologisch Centrum Zuid
Human Papillomavirus (HPV) Vaccine, Human Papillomavirus (HPV) Vaccines
Strengthening HPV Vaccination and Adolescent Health Research Program in Nigeria (SHARP)
The goal of this clinical trial is to learn whether adding adolescent health services to routine government health programs can increase Human Papillomavirus (HPV) vaccination coverage among 9-year-old girls and improve use of…
- Conditions
- Human Papillomavirus (HPV) Vaccine, Human Papillomavirus (HPV) Vaccines, Human Papillomavirus (HPV) Infections, Adolescent Health Services
- Trial name
- SHARP (NCT07200414)
- Testing
- Integrated Adolescent Health Package, Routine Government Health Services
- Where
- Nigeria
- Volunteers
- 12,654 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HPV Infections
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
A randomized, double-blind and placebo-controlled phase I study to evaluate the safety and immunogenicity of a 9-valent Human Papillomavirus (HPV) vaccine, administered intramuscularly according to a 0, 2, 6-month schedule in 9…
- Trial name
- NCT03900572
- Testing
- HPV Vaccine
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
CDKN2A-p16 Positive, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer
This phase II trial studies how well alpelisib works in treating participants with human papillomavirus(HPV)-associated stage I-IVA head and neck cancer that can be removed by surgery.
- Conditions
- CDKN2A-p16 Positive, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma AJCC V7, Stage II Oropharyngeal Squamous Cell Carcinoma AJCC V7
- Trial name
- NCT03601507
- Testing
- Alpelisib, Laboratory Biomarker Analysis, Pharmacodynamic Study
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Arizona
Human Papillomavirus Infection
Comparative Effectiveness of System Interventions to Increase HPV Vaccine Receipt in FQHCs
UCLA and Northeast Valley Health Center (NEVHC), a large, multi-site Federally Qualified Health Center (FQHC), are partnering to address underutilization of the prophylactic HPV vaccine among underserved, ethnic minority…
- Trial name
- NCT03726151
- Testing
- Parent Reminders, Multicomponent clinic-system strategies, Combined Condition
- Where
- 7 sites in United States
- Volunteers
- 17,000 people
- Sponsor
- University of California, Los Angeles
Cervical Cancers, Vulvar Cancers
A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)
This study will evaluate whether V503 (9vHPV vaccine), is well tolerated in girls and women between 12 and 26 years old who have previously been vaccinated with GARDASIL™.
- Conditions
- Cervical Cancers, Vulvar Cancers, Vaginal Cancers, Genital Warts
- Trial name
- NCT01047345
- Testing
- V503
- Volunteers
- 924 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HPV Vaccine Acceptability
Impact of a School- and Primary Care-based Multicomponent Intervention on HPV Vaccination Acceptability
This study aims at evaluating the effectiveness, efficiency and implementation of a multicomponent intervention (components being applied in combination or alone) on the acceptability of HPV vaccine among French adolescents…
- Trial name
- PrevHPV (NCT04945655)
- Testing
- Adolescents and parents' education and motivation at school (component 1), General practitioners' training (component 2), Access to vaccination at school (component 3)
- Where
- France
- Volunteers
- 30,739 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France